Abion Inc.
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid c… Read more
Abion Inc. - Asset Resilience Ratio
Abion Inc. (203400) has an Asset Resilience Ratio of 3.37% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Abion Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Abion Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.67 Billion | 3.37% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩1.67 Billion | 3.37% |
Asset Resilience Insights
- Limited Liquidity: Abion Inc. maintains only 3.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Abion Inc. Industry Peers by Asset Resilience Ratio
Compare Abion Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Abion Inc. (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Abion Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.97% | ₩3.17 Billion | ₩63.78 Billion | -19.06pp |
| 2023-12-31 | 24.03% | ₩10.73 Billion | ₩44.67 Billion | -47.58pp |
| 2022-12-31 | 71.61% | ₩17.29 Billion | ₩24.14 Billion | -12.72pp |
| 2021-12-31 | 84.33% | ₩37.63 Billion | ₩44.62 Billion | +30.15pp |
| 2020-12-31 | 54.17% | ₩7.24 Billion | ₩13.37 Billion | +15.65pp |
| 2019-12-31 | 38.53% | ₩3.66 Billion | ₩9.49 Billion | +17.27pp |
| 2018-12-31 | 21.26% | ₩1.68 Billion | ₩7.90 Billion | -4.07pp |
| 2017-12-31 | 25.33% | ₩2.12 Billion | ₩8.35 Billion | -17.27pp |
| 2016-12-31 | 42.60% | ₩5.52 Billion | ₩12.95 Billion | -- |